<DOC>
	<DOCNO>NCT02542410</DOCNO>
	<brief_summary>The propose pilot study estimate efficacy safety novel therapeutic agent , cabergoline , clinical standard therapy , norethindrone acetate , treatment endometriosis-associated pain young woman endometriosis .</brief_summary>
	<brief_title>Dopamine Receptor Agonist Therapy Pain Relief Women Suffering From Endometriosis : A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Cabergoline</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<mesh_term>Norethindrone acetate</mesh_term>
	<mesh_term>Norethindrone</mesh_term>
	<criteria>Surgically confirm endometriosis Age 1835 , premenopausal Pelvic pain score â‰¥3 Visual Analog Scaleover last month Use concurrent hormone medication ( birth control pill ) Impaired liver function ( ALT &gt; 2x normal ) liver disease ( cirrhosis , hepatitis ) Pregnancy Breast cancer Active thromboembolic disease Uncontrolled hypertension , history cardiac valve disorder , history fibrotic disorder</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>